6G1V

Crystal structure of Torpedo Californica acetylcholinesterase in complex with 12-Amino-3-chloro-6,7,10,11-tetrahydro-5,9-dimethyl-7,11-methanocycloocta[b]quinolin-5-ium

Replaces:  6FOU

Summary for 6G1V

• Entry DOI: 10.2210/pdb6g1v/pdb
• Descriptor: Acetylcholinesterase, 2-acetamido-2-deoxy-beta-D-glucopyranose, 12-Amino-3-chloro-6,7,10,11-tetrahydro-5,9-dimethyl-7,11-methanocycloocta[b]quinolin-5-ium, ... (6 entities in total)
• Functional Keywords: torpedo californica acetylcholinesterase, ad, alzheimer disease, hydrolase
• Biological source: Tetronarce californica (Pacific electric ray)
• Total number of polymer chains: 2
• Total formula weight: 129943.04

Authors

Coquelle, N.,Colletier, J.P. (deposition date: 2018-03-22, release date: 2018-04-04, Last modification date: 2024-10-23)

Primary citation

Galdeano, C.,Coquelle, N.,Cieslikiewicz-Bouet, M.,Bartolini, M.,Perez, B.,Clos, M.V.,Silman, I.,Jean, L.,Colletier, J.P.,Renard, P.Y.,Munoz-Torrero, D.
Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis.
Molecules, 23:-, 2018

PubMed Abstract: Symptomatic treatment of myasthenia gravis is based on the use of peripherally-acting acetylcholinesterase (AChE) inhibitors that, in some cases, must be discontinued due to the occurrence of a number of side-effects. Thus, new AChE inhibitors are being developed and investigated for their potential use against this disease. Here, we have explored two alternative approaches to get access to peripherally-acting AChE inhibitors as new agents against myasthenia gravis, by structural modification of the brain permeable anti-Alzheimer AChE inhibitors tacrine, 6-chlorotacrine, and huprine Y. Both quaternization upon methylation of the quinoline nitrogen atom, and tethering of a triazole ring, with, in some cases, the additional incorporation of a polyphenol-like moiety, result in more polar compounds with higher inhibitory activity against human AChE (up to 190-fold) and butyrylcholinesterase (up to 40-fold) than pyridostigmine, the standard drug for symptomatic treatment of myasthenia gravis. The novel compounds are furthermore devoid of brain permeability, thereby emerging as interesting leads against myasthenia gravis.

PubMed: 29534488
DOI: 10.3390/molecules23030634

Experimental method

X-RAY DIFFRACTION (1.82 Å)